Press Releases

Ipsen’s Kayfanda® (odevixibat) approved in European Union for cholestatic pruritus in Alagille Syndrome, a rare…

Ipsen’s Iqirvo® (elafibranor) approved in the European Union as first new treatment for primary biliary…

Ipsen delivers strong results in the first half of 2024, progresses on launches and upgrades…

Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the…

Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary…

Ipsen presents long-term elafibranor efficacy and itch-related quality of life data in patients with primary…

Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms &…

Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases

Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors

Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by…